NDA 020385 · Pfizer INC
Nicotrol
Nicotine · Nasal · Cholinergic Nicotinic Agonist
Last checked: Nov 19, 2026Latest source record: May 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Mar 22, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
911
103 Phase 3, 74 recruiting
FAERS reports
17,295
11,425 serious, 1,618 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 29, 2025.
INDICATIONS AND USAGE NICOTROL NS is indicated as an aid to smoking cessation for the relief of nicotine withdrawal symptoms. NICOTROL NS therapy should be used as a part of a comprehensive behavioral smoking cessation program. The safety and efficacy of the continued use of NICOTROL NS for periods longer than 6 months have not been adequately studied and such use is not recommended.
Mechanism: Pharmacologic Action Nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of nicotine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses, the stimulant effects predominate while at high doses the reward effects predominate. Intermittent...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
- NICOTROL · NICOTINE 0.5MG/SPRAY · SPRAY, METERED, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nicotine" as an intervention, any sponsor and status, largest first.
- Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVEPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00461630 · 25,673 participants · Start Jan 2007 · Primary completion Oct 2012
Drug: ER niacin/laropiprant; simvastatin and 1 more · For: Cardiovascular Disease; Peripheral Arterial Disease; Diabetes Mellitus and 1 more
Sites: Oxford, United Kingdom
- BREATHE 2 Clinic Stop-Smoking Treatment Outreach StudyPivotal-lookingCompleted
University of Wisconsin, MadisonAcademic, hospital or other
NCT05683821 · 12,376 participants · Start Jul 24, 2023 · Primary completion May 7, 2025
Drug: Nicotine replacement therapy sampling · For: Quitting Smoking; Smoking Cessation; Smoking, Cigarette
Sites: Madison, Wisconsin
- Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric DisordersPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01456936 · 8,144 participants · Start Nov 2011 · Primary completion Jan 2015
Drug: Placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Phoenix, Arizona; Encino, California · 156 sites in all
Centre for Addiction and Mental HealthAcademic, hospital or other
NCT00356993 · 6,009 participants · Start Oct 2005 · Primary completion Mar 30, 2018
Drug: Nicotine Replacement Therapy · For: Smoking
Sites: Toronto, Canada
- Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01574703 · 4,595 participants · Start May 2012 · Primary completion Jul 2015
Drug: placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Encino, California; Escondido, California · 134 sites in all
- Telephone Counseling and the Distribution of Nicotine Patches to SmokersPivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT00851357 · 4,200 participants · Start Feb 2009 · Primary completion Oct 2010
Drug: Nicotine Patch; Placebo · For: Smoking Cessation
Sites: San Diego, California
- A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' HelplinePivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT01502306 · 3,816 participants · Start Jun 2012 · Primary completion Feb 2014
Drug: Nicotine patches · For: Smoking Cessation
Sites: San Diego, California
- Providing Free Nicotine Patches to Quitline SmokersPivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT01736085 · 3,706 participants · Start Apr 2013 · Primary completion Nov 2014
Drug: Nicotine patches · For: Smoking Cessation
Sites: San Diego, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,091
- nausea1,137
- headache789
- overdose780
- foetal exposure during pregnancy755
- nicotine dependence741
- product adhesion issue734
- dyspnoea683
- treatment noncompliance672
- malaise671
- pain632
- dizziness629
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 240 |
| 2005 | 233 |
| 2006 | 331 |
| 2007 | 445 |
| 2008 | 329 |
| 2009 | 455 |
| 2010 | 758 |
| 2011 | 701 |
| 2012 | 792 |
| 2013 | 491 |
| 2014 | 625 |
| 2015 | 713 |
| 2016 | 854 |
| 2017 | 750 |
| 2018 | 2,020 |
| 2019 | 1,265 |
| 2020 | 1,203 |
| 2021 | 934 |
| 2022 | 909 |
| 2023 | 896 |
| 2024 | 902 |
| 2025 | 847 |
| 2026 | 602 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nicotrol (Nicotine)
2024 spending
$740K
Beneficiaries
824
1,297 claims
Per beneficiary
$899
$2.94 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,638,110 |
| 2021 | $17,840,443 |
| 2022 | $18,560,286 |
| 2023 | $15,332,026 |
| 2024 | $740,371 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Electronic cigarettes for smoking cessation.
Lindson N, Butler AR, McRobbie H, et al. · Cochrane Database Syst Rev 2024 · Network Meta-Analysis, Systematic Review
- Nicotine replacement therapy versus control for smoking cessation.
Hartmann-Boyce J, Chepkin SC, Ye W, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Systematic Review
- Interventions for quitting vaping.
Butler AR, Lindson N, Livingstone-Banks J, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- Electronic cigarettes for smoking cessation.
Lindson N, Butler AR, McRobbie H, et al. · Cochrane Database Syst Rev 2025 · Network Meta-Analysis, Systematic Review
- Electronic cigarettes for smoking cessation.
Lindson N, Livingstone-Banks J, Butler AR, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.
Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. · Cochrane Database Syst Rev 2023 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.